Stayble Therapeutics publishes half-year report for 2022
Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes the half-year report for 2022. The report is available as an attached document and on the Company's website.Highlights during the second quarter (April – June 2022) · Stayble announces that it has enrolled 75% of all patients in the ongoing Phase IIb clinical trial. Multiple efforts to increase patient enrollment coupled with the reduced impact of the Covid-19 pandemic have resulted in a significant increase in recruitment rates. The recruitment rate is in line with the set timeline and the final target to enroll all